EAM
COGT icon

Eventide Asset Management’s Cogent Biosciences COGT Stock Holding History

Eventide Asset Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-919,635
Closed -$9.93M – 209
2024
Q3 		$9.93M Sell
919,635
-479,357
-34% -$4.67M 0.17% 121
2024
Q2 		$11.8M Buy
+1,398,992
New +$10.6M 0.2% 119
2024
Q1 		– Sell
-2,232,968
Closed -$13.1M – 164
2023
Q4 		$13.1M Buy
2,232,968
+82,968
+4% +$636K 0.21% 110
2023
Q3 		$21M Sell
2,150,000
-1,290,796
-38% -$15.3M 0.38% 79
2023
Q2 		$40.7M Buy
3,440,796
+851,018
+33% +$9.76M 0.69% 49
2023
Q1 		$27.9M Hold
2,589,778
– – 0.51% 64
2022
Q4 		$29.9M Sell
2,589,778
-271,114
-9% -$3.36M 0.59% 55
2022
Q3 		$42.7M Sell
2,860,892
-2,234,108
-44% -$30.6M 0.84% 45
2022
Q2 		$46M Buy
5,095,000
+1,195,000
+31% +$8.16M 0.98% 40
2022
Q1 		$29.2M Buy
3,900,000
+385,091
+11% +$2.68M 0.46% 65
2021
Q4 		$30.2M Buy
+3,514,909
New +$30.6M 0.39% 76

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Eventide Asset Management's COGT Position: Q4 2024 in Review

Eventide Asset Management sold out of Cogent Biosciences (COGT) in Q4 2024, closing a stake of 919,635 shares — an estimated $9.93M sold.

Eventide Asset Management first reported a position in COGT in Q4 2021 and held it in 11 quarters. The position peaked at $46M in Q2 2022. 176 funds tracked by Wall St. Rank hold COGT as of Q4 2024.

  • Eventide Asset Management reported no remaining Cogent Biosciences position as of Q4 2024 after selling out during the quarter.
  • Eventide Asset Management sold 919,635 Cogent Biosciences shares in Q4 2024, an estimated $9.93M.
  • Eventide Asset Management first reported a position in Cogent Biosciences in Q4 2021 and held it in 11 quarters.
  • Eventide Asset Management's Cogent Biosciences position peaked at $46M in Q2 2022.
  • 176 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2024.

Based on Eventide Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.